drugset / Trial / NCT05679921
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |